

## Fucoxanthin prevents H<sub>2</sub>O<sub>2</sub>-induced neuronal apoptosis via concurrently activating the PI3-K/Akt cascade and inhibiting the ERK pathway

Jie Yu<sup>a</sup>, Jia-Jia Lin<sup>a</sup>, Rui Yu<sup>a</sup>, Shan He<sup>b</sup>, Qin-Wen Wang<sup>a</sup>, Wei Cui<sup>a</sup> and Jin-Rong Zhang<sup>b</sup>

<sup>a</sup>Ningbo Key Laboratory of Behavioral Neuroscience, Department of Physiology, School of Medicine, Ningbo University, Ningbo, PR China;

<sup>b</sup>School of Marine Sciences, Ningbo University, Ningbo, Ningbo, PR China

### ABSTRACT

**Background:** As a natural carotenoid abundant in chloroplasts of edible brown algae, fucoxanthin possesses various health benefits, including anti-oxidative activity in particular.

**Objective:** In the present study, we studied whether fucoxanthin protected against hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-induced neuronal apoptosis.

**Design:** The neuroprotective effects of fucoxanthin on H<sub>2</sub>O<sub>2</sub>-induced toxicity were studied in both SH-SY5Y cells and primary cerebellar granule neurons.

**Results:** Fucoxanthin significantly protected against H<sub>2</sub>O<sub>2</sub>-induced neuronal apoptosis and intracellular reactive oxygen species. H<sub>2</sub>O<sub>2</sub> treatment led to the reduced activity of phosphoinositide 3-kinase (PI3-K)/Akt cascade and the increased activity of extracellular signal-regulated kinase (ERK) pathway in SH-SY5Y cells. Moreover, fucoxanthin significantly restored the altered activities of PI3-K/Akt and ERK pathways induced by H<sub>2</sub>O<sub>2</sub>. Both specific inhibitors of glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ) and mitogen-activated protein kinase (MEK) significantly protected against H<sub>2</sub>O<sub>2</sub>-induced neuronal death. Furthermore, the neuroprotective effects of fucoxanthin against H<sub>2</sub>O<sub>2</sub>-induced neuronal death were abolished by specific PI3-K inhibitors.

**Conclusions:** Our data strongly revealed that fucoxanthin protected against H<sub>2</sub>O<sub>2</sub>-induced neurotoxicity via concurrently activating the PI3-K/Akt cascade and inhibiting the ERK pathway, providing support for the use of fucoxanthin to treat neurodegenerative disorders induced by oxidative stress.

### ARTICLE HISTORY

Received 21 December 2016

Accepted 28 February 2017

### KEYWORDS

Fucoxanthin;  
neurodegenerative  
disorders; H<sub>2</sub>O<sub>2</sub>; Akt; ERK





### Introduction

Oxidative stress plays a critical role in neuronal loss of neurodegenerative disorders.[1] Excessive reactive oxygen species (ROS), including hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), nitric oxide and highly reactive hydroxyl radicals, are released after the neuron injury during oxidative stress. ROS further promote neurotoxicity via interacting with macromolecules and regulating signaling pathways.[2] Among various ROS, H<sub>2</sub>O<sub>2</sub> is widely used to establish oxidative stress-induced neurotoxicity model *in vitro*.[3] H<sub>2</sub>O<sub>2</sub>-induced neurotoxicity is regulated by the inhibition of pro-survival pathways, such as the phosphoinositide 3-kinase (PI3-K)/Akt cascade, and/or the activation of pro-apoptotic pathways, such as the mitogen-activated protein kinase (MAPK) pathway. Inhibition of PI3-K/Akt cascade consequently activates glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ), a molecule involved in H<sub>2</sub>O<sub>2</sub>-induced neuronal apoptosis.[4,5] In addition, extracellular signal-regulated kinase (ERK), a key intermediate of the MAPK pathway,

has been regarded as a main pro-apoptotic molecule involved in H<sub>2</sub>O<sub>2</sub>-induced neurotoxicity.[5,6]

Fucoxanthin is one of the most abundant marine carotenoids found in edible brown seaweeds.[7] Previous investigations have reported that fucoxanthin possesses different health benefits, including anti-oxidative activity in particular.[8–10] Fucoxanthin significantly reduces weight gain in animals through enhancing fatty acid oxidation in white adipose tissue.[11] Moreover, fucoxanthin-fed animals display reduced levels of oxidative stress markers, as well as enhanced activities of antioxidant enzymes.[12] Fucoxanthin has also been reported to produce anti-oxidative property in various *in vitro* models, including A $\beta$ <sub>42</sub>-treated microglia cells, ferric nitrilotriacetate-treated hepatic cells and UV-induced fibroblast cells.[13–16] However, it remains unclear whether fucoxanthin could protect neuronal cells against oxidative stress-related neurotoxicity.

As human neuroblastoma, SH-SY5Y cells are sensitive to oxidants.[17] Therefore, SH-SY5Y cells are used

**CONTACT** Wei Cui  [cuiwei@nbu.edu.cn](mailto:cuiwei@nbu.edu.cn)  Department of Physiology, School of Medicine, Ningbo University, Zhejiang, PR China; Jin-Rong Zhang  [zhangjinrong@nbu.edu.cn](mailto:zhangjinrong@nbu.edu.cn)  School of Marine Sciences, Ningbo University, Zhejiang, PR China

© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

as cellular models to explore the molecular mechanisms of oxidative stress-induced neurotoxicity.[18,19] Moreover, homogenous cerebellar granule neurons (CGNs) can be easily obtained because more than 90% of cells in cerebellum are CGNs.[20] Therefore, CGNs are widely used as a model of primary neurons to examine neuroprotective chemicals.

In our study, we showed that fucoxanthin effectively protected against H<sub>2</sub>O<sub>2</sub>-induced neurotoxicity in both SH-SY5Y cells and primary CGNs. Our results also demonstrated that fucoxanthin exerted such neuroprotective effects via concurrently activating the PI3-K/Akt cascade and inhibiting the ERK pathway.

## Materials and methods

### Chemicals and reagents

Fucoxanthin was extracted from *Sargassum horneri* using a series of steps, including solvent extraction, ethanol precipitation and low-temperature concentration. Briefly, fucoxanthin isolation was conducted at 30°C for 2 h with ethanol to sample ratio of 4:1 (v/w). Then the fucoxanthin-containing solution was concentrated at 25°C. Lipid and chlorophylls were precipitated when the ethanol content reached 63% in the concentrated solution. Fucoxanthin was purified by precipitation when the ethanol content reached 40% in the solution. The purity of fucoxanthin was more than 90% by HPLC, and purified fucoxanthin was stored at -20°C prior to further analysis. H<sub>2</sub>O<sub>2</sub> was purchased from Calbiochem (San Diego, CA, USA). SB415286 was purchased from Sigma Chemicals (St Louis, MO, USA). U0126, Wortmannin and LY294002 were supplied from LC Laboratories (Woburn, MA, USA). Antibodies against pSer473-Akt, Akt, pSer9-GSK3β, GSK3β, pERK and ERK were provided by Cell Signaling Technology (Beverly, MA, USA). Unless otherwise noted, all media and supplements for cell cultures were obtained from Invitrogen (Carlsbad, CA, USA).

### Culture of SH-SY5Y cells

SH-SY5Y cells were purchased from the Shanghai Institute of Cell Biology (Chinese Academy of Sciences, Shanghai, China) and maintained in high glucose modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin (100 U ml<sup>-1</sup>)/streptomycin (100 μg ml<sup>-1</sup>) at 37°C with 5% CO<sub>2</sub> in a humidified environment. The medium was refreshed every other day. For the H<sub>2</sub>O<sub>2</sub> experiment, SH-SY5Y cells in DMEM with low serum

content (1% FBS) were seeded in six-well or 96-well plates at a density of 1 × 10<sup>5</sup> cells ml<sup>-1</sup> for 24 h before further experiments.

### Culture of primary CGNs

CGNs were isolated from eight-day-old Sprague-Dawley rats as previously described.[21] Briefly, cells were seeded at a density of 2.7 × 10<sup>5</sup> cells cm<sup>-2</sup> and maintained in basal modified Eagle's medium supplemented with 10% FBS, 25 mM KCl, 2 mM glutamine and penicillin (100 U ml<sup>-1</sup>)/streptomycin (100 μg ml<sup>-1</sup>) for 24 h. Subsequently, cytosine arabinoside (10 μM) was added to the medium to inhibit the growth of non-neuronal cells. Granule cells were identified according to several criteria, including their size, shape and relative proportion of the total cell population.

### Measurement of cell viability

Cell viability was assessed by the 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay based on previous protocol.[22,23] Briefly, 10 μl of MTT solution (5 mg ml<sup>-1</sup>) was added to each well after treatment. Plates were incubated at 37°C for 4 h in a humidified incubator. Subsequently, 100 μl of the solvating solution (0.01 N HCl in 10% SDS solution) was then added to each well, followed by incubation for 16–20 h. The absorbance of the samples was determined at a wavelength of 570 nm with 655 nm as a reference wavelength. Unless otherwise indicated, the extent of MTT conversion in cells was expressed as a percentage of the control without treatment.

### Fluorescein diacetate/propidium iodide double staining assay

Viable cells were visualized by the fluorescein formed from fluorescein diacetate (FDA) by esterase activity in viable cells. Non-viable cells were analyzed by propidium iodide (PI) staining, which only penetrates the membranes of dead cells. Briefly, the cells were examined after incubation with 10 μg ml<sup>-1</sup> of FDA and 5 μg ml<sup>-1</sup> of PI for 15 min. Images were acquired using UV light microscopy and compared with those taken under phase-contrast microscopy. To quantitatively evaluate cell viability, images of each well were taken from five randomly selected fields, and the number of PI-positive cells and FDA-positive cells was counted. The number of FDA-positive cells was then averaged using the equation as follows: % of cell viability = [number of FDA-positive cells / (number of PI-

positive cells + number of FDA-positive cells]  $\times$  100%.[24]

### Hoechst staining

Chromatin condensation was evaluated by staining the cell nuclei with Hoechst 33,342 as previously described.[25,26] After treatment, cells were washed with ice-cold phosphate buffered saline (PBS), fixed with 4% formaldehyde for 15 min, membrane-permeabilized in 0.1% Triton X-100 for 15 min, and blocked in 1% bovine serum albumin (BSA) for 15 min. Cells were then stained with Hoechst 33,342 ( $5 \mu\text{g ml}^{-1}$ ) at  $4^\circ\text{C}$  for 5 min. Images were obtained using a fluorescence microscope (Nikon Instruments Inc., Melville, NY, USA) at  $100\times$  magnification. Ultraviolet excitation and emission wavelengths were used to obtain images of nuclei labeled with Hoechst-33342. To determine the proportion of apoptotic nuclei in each group, images of each well were taken from five randomly selected fields, and the number of pyknotic nuclei and total nuclei was counted. The percentage of pyknotic nuclei was then averaged.

### Measurement of intracellular ROS

Intracellular ROS was measured by 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA, Molecular Probes, Eugene, OR, USA), a fluorescent dye which could be converted to membrane impermeable derivative DCFH. [27] In the presence of intracellular ROS, DCFH is oxidized to highly fluorescent 2',7'-dichlorofluorescein (DCF). Cells were washed with PBS and incubated with  $10 \mu\text{M}$  DCFH-DA at  $37^\circ\text{C}$  for 15 min. The dye was removed, and cells were washed with PBS and scanned with a plate reader (Wallac, PerkinElmer, Waltham, MA, USA) at 485 nm excitation and 520 nm emission. Images were acquired using a fluorescence microscope (Nikon Instruments Inc.).

### Western blot analysis

Western blotting was performed using a well-established protocol.[28] Cell lysates were separated on SDS-polyacrylamide gels and electrotransferred onto polyvinylidene difluoride membranes. After membrane blocking, proteins were detected using primary antibodies. After incubation at  $4^\circ\text{C}$  overnight, signals were obtained after incubation with HRP-conjugated secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Subsequently, blots were developed using the enhanced chemiluminescence plus kit

(Amersham Bioscience, Aylesbury, UK) and signals were exposed to autoradiographic film.


### Statistical analysis

Results were expressed as mean  $\pm$  SEM. Differences among groups were compared by analysis of variance (ANOVA) followed by Dunnett's or Tukey's test.  $P < 0.05$  was considered as statistically significant.

## Results

### Fucoxanthin reduces $\text{H}_2\text{O}_2$ -induced neuronal apoptosis in SH-SY5Y cells

In the present study, SH-SY5Y cells were first pre-treated with fucoxanthin ranging from 0.3 to  $3 \mu\text{M}$  for 2 h, followed by treatment with  $150 \mu\text{M}$   $\text{H}_2\text{O}_2$  for 24 h. Cell viability was determined by the MTT assay. Figure 1(a) shows that fucoxanthin significantly



**Figure 1.** Fucoxanthin protects against  $\text{H}_2\text{O}_2$ -induced cell death in a dose-dependent manner. (a) SH-SY5Y cells were treated with fucoxanthin. After 2 h, cells were exposed to  $150 \mu\text{M}$   $\text{H}_2\text{O}_2$ . MTT assay was used to measure cell viability at the 24 h after  $\text{H}_2\text{O}_2$  exposure. Data, expressed as the percentage of control, were presented as the mean  $\pm$  SEM of three separate experiments; ## $p < 0.01$  vs. the control group, \*\* $p < 0.01$  vs. the  $\text{H}_2\text{O}_2$ -challenged group (ANOVA and Tukey's test). (b) SH-SY5Y cells were administrated with  $3 \mu\text{M}$  fucoxanthin for 2 h, and exposed to  $150 \mu\text{M}$   $\text{H}_2\text{O}_2$ . After 24 h, cells were examined by FDA/PI double staining.

reduced  $H_2O_2$ -induced neuronal death in a dose-dependent manner. The cell viability in  $H_2O_2$ , 1  $\mu M$  fucoxanthin +  $H_2O_2$  and 3  $\mu M$  fucoxanthin +  $H_2O_2$  groups were 52.4, 79.0 and 98.1%, respectively. Treatment with 3  $\mu M$  fucoxanthin alone for 26 h was not cytotoxic and did not alter cell proliferation (data not shown). To further elucidate the neuroprotective effect of fucoxanthin against  $H_2O_2$ -induced neurotoxicity, SH-SY5Y cells were analyzed by FDA/PI double staining. Figure 1(b) exhibits that fucoxanthin blocked the loss of neurons induced by  $H_2O_2$ . Moreover, fucoxanthin significantly decreased  $H_2O_2$ -induced neuronal apoptosis in SH-SY5Y cells (Figure 2).


### Fucoxanthin reduces $H_2O_2$ -induced neuronal death in primary CGNs

We have previously demonstrated that the treatment of 30  $\mu M$   $H_2O_2$  for 6 h leads to significant neuronal death in CGNs.[29] Therefore, we further investigated


whether fucoxanthin could produce neuroprotective effects in CGNs. CGNs were pre-treated with fucoxanthin for 2 h, and then treated with 30  $\mu M$   $H_2O_2$  for another 6 h. CGNs were examined by FDA/PI double staining. Figure 3 displays that treatment of 3  $\mu M$  fucoxanthin significantly reduced  $H_2O_2$ -induced neuronal death in CGNs. The cell viability in  $H_2O_2$  and 3  $\mu M$  fucoxanthin +  $H_2O_2$  groups were 48.8% and 73.4%, respectively. Treatment with 3  $\mu M$  fucoxanthin alone for 26 h did not alter cell viability in CGNs (data not shown).

### Fucoxanthin reduces $H_2O_2$ -induced intracellular ROS in SH-SY5Y cells

We have also measured intracellular ROS by using DCF-DA. We found that  $H_2O_2$  significantly increased intracellular ROS in SH-SY5Y cells (Figure 4). Moreover, fucoxanthin significantly reversed the increased intracellular ROS induced by



**Figure 2.** Fucoxanthin significantly protects against  $H_2O_2$ -induced apoptosis in SH-SY5Y cells. SH-SY5Y cells were treated with 3  $\mu M$  fucoxanthin. After 2 h, cells were exposed to 150  $\mu M$   $H_2O_2$ . Cells were measured by Hoechst staining at 24 hours after  $H_2O_2$  challenge. The number of pyknotic nuclei was counted. Data were presented as the mean  $\pm$  SEM of three separate experiments; ##  $p < 0.01$  vs. the control group, \*\*  $p < 0.01$  vs. the  $H_2O_2$ -challenged group (ANOVA and Tukey's test). Array: representative pyknotic nuclei.




**Figure 3.** Fucoxanthin reduces H<sub>2</sub>O<sub>2</sub>-induced cell death in primary CGNs. (a) CGNs were administrated with 3 μM fucoxanthin (Fuco). After 2 h, cells were exposed to 30 μM H<sub>2</sub>O<sub>2</sub>. At 6 h after H<sub>2</sub>O<sub>2</sub> exposure, CGNs were analyzed by FDA/PI staining. Cell viability was analyzed from representative photomicrographs. Data were presented as the mean ± SEM of three separate experiments; <sup>##</sup>*p* < 0.01 vs. the control group, <sup>\*\*</sup>*p* < 0.01 vs. the H<sub>2</sub>O<sub>2</sub>-challenged group (ANOVA and Tukey's test).

H<sub>2</sub>O<sub>2</sub>. These results suggested that H<sub>2</sub>O<sub>2</sub> could induce oxidative stress which could be decreased by fucoxanthin.

### **Inhibiting the PI3-K/Akt cascade and activating the ERK signaling are involved in H<sub>2</sub>O<sub>2</sub>-induced neurotoxicity in SH-SY5Y cells**

Previous studies have reported that inhibition of the PI3-K/Akt cascade and activation of the ERK signaling are involved in the neurotoxicity induced by oxidative stress.[4,5] Therefore, we assessed whether the alteration of these pathways was also involved in our model. Figure 5 shows that H<sub>2</sub>O<sub>2</sub> decreased pSer473-Akt and pSer9-GSK3β levels in SH-SY5Y cells. Moreover, the level of pERK was significantly increased during first 30 min post-treatment, although it returned to its basal




**Figure 4.** Fucoxanthin significantly protected against H<sub>2</sub>O<sub>2</sub>-induced increase of intracellular ROS in SH-SY5Y cells. SH-SY5Y cells were treated with 3 μM fucoxanthin. After 2 h, cells were exposed to 150 μM H<sub>2</sub>O<sub>2</sub>. Intracellular ROS was measured by DCF-DA assay at 2 h after H<sub>2</sub>O<sub>2</sub> challenge. Data were presented as the mean ± SEM of three separate experiments; <sup>##</sup>*p* < 0.01 vs. the control group, <sup>\*\*</sup>*p* < 0.01 vs. the H<sub>2</sub>O<sub>2</sub>-challenged group (ANOVA and Tukey's test).


level 3 h after H<sub>2</sub>O<sub>2</sub> challenge (Figure 6). Furthermore, SB415286, a specific inhibitor of GSK3β, and U0126, a specific inhibitor of mitogen-activated protein kinase kinase (MEK), significantly protected against H<sub>2</sub>O<sub>2</sub>-induced neuronal death (Figure 7). Interestingly, co-application of SB415286 and U0126 significantly produced the neuroprotective effects, which were similar to those of fucoxanthin. Taken together, these results suggested that inhibition of the PI3-K/Akt cascade and activation of the ERK signaling were involved in the H<sub>2</sub>O<sub>2</sub>-induced neurotoxicity in SH-SY5Y cells. In addition, fucoxanthin might protect against H<sub>2</sub>O<sub>2</sub>-induced neurotoxicity via regulating these signaling pathways.

### **Fucoxanthin protects against the inhibition of the PI3-K/Akt cascade induced by H<sub>2</sub>O<sub>2</sub>**

To examine whether fucoxanthin produced neuroprotective effects via the modulation of the PI3-K/Akt cascade, we assessed the levels of pSer473-Akt and pSer9-GSK3β. Figure 8 shows that pre-treatment with 3 μM fucoxanthin significantly reversed the



**Figure 5.** H<sub>2</sub>O<sub>2</sub> decreases pSer473-Akt and pSer9-GSK3β in a time-dependent manner. SH-SY5Y cells were treated with 150 μM H<sub>2</sub>O<sub>2</sub> for various durations as indicated. Western blot analysis was used to assess the expression of (a) pSer473-Akt and (b) pSer9-GSK3β. Data were presented as the mean ± SEM of three separate experiments; \**p* < 0.05 and \*\**p* < 0.01 vs. control group (ANOVA and Dunnett's test).




**Figure 6.** H<sub>2</sub>O<sub>2</sub> increases the level of pERK in SH-SY5Y cells. SH-SY5Y cells were treated with 150 μM H<sub>2</sub>O<sub>2</sub> for various durations as indicated. Western blot was used to analyze pERK. Data were presented as the mean ± SEM of three separate experiments; \*\**p* < 0.01 vs. control group (ANOVA and Dunnett's test).


decrease of both pSer473-Akt and pSer9-GSK3β induced by H<sub>2</sub>O<sub>2</sub>). Additionally, LY294002 and wortmannin, two PI3-K specific inhibitors, were used.

**Figure 7.** GSK3β and MEK specific inhibitors protect against H<sub>2</sub>O<sub>2</sub>-induced cell death. SH-SY5Y cells were treated with SB415286, U0126 or SB415286 + U0126 (SB+U) at the indicated concentrations. After 2 h, cells were exposed to 150 μM H<sub>2</sub>O<sub>2</sub>. Cell viability was analyzed by MTT assay at 24 h after H<sub>2</sub>O<sub>2</sub> exposure. Data were presented as the mean ± SEM of three separate experiments; ##*p* < 0.01 vs. the control group, \**p* < 0.05 and \*\**p* < 0.01 vs. H<sub>2</sub>O<sub>2</sub>-treated group, &*p* < 0.05 vs. H<sub>2</sub>O<sub>2</sub> + 20 μM SB415286 group (ANOVA and Tukey's test).

**Figure 9** shows that the inhibition of PI3-K by either LY294002 or wortmannin significantly abolished the neuroprotective effects of fucoxanthin, suggesting that fucoxanthin protected against H<sub>2</sub>O<sub>2</sub>-induced neuronal death via reversing the inhibition of PI3-K/Akt cascade.



**Figure 8.** Fucoxanthin protects against H<sub>2</sub>O<sub>2</sub>-induced decrease of pSer473-Akt and pSer9-GSK3β. SH-SY5Y cells were treated with fucoxanthin. After 2 h, cells were exposed to 150 μM H<sub>2</sub>O<sub>2</sub>. Western blot was used to analyze (a) pSer473-Akt and (b) pSer9-GSK3β at 3 h after H<sub>2</sub>O<sub>2</sub> treatment. Data were presented as the mean ± SEM of three separate experiments; ##*p* < 0.01 vs. the control group, \**p* < 0.05 and \*\**p* < 0.01 vs. H<sub>2</sub>O<sub>2</sub>-treated group (ANOVA and Tukey's test).



**Figure 9.** PI3-K specific inhibitors abolish the neuroprotective effects of fucoxanthin. SH-SY5Y cells were pre-treated with LY294002 (LY) or wortmannin (Wort) for 0.5 h, and then treated with 3 μM fucoxanthin for 4 h before the exposure to 150 μM H<sub>2</sub>O<sub>2</sub>. MTT assay was used to measure cell viability at 24 h after H<sub>2</sub>O<sub>2</sub> treatment. Data were presented as the mean ± SEM of three separate experiments; ##*p* < 0.01 vs. the control group, \*\**p* < 0.01 vs. H<sub>2</sub>O<sub>2</sub>-treated group, &&*p* < 0.01 vs. H<sub>2</sub>O<sub>2</sub> plus fucoxanthin group (ANOVA and Tukey's test).


### Fucoxanthin reduces the activation of ERK signaling induced by H<sub>2</sub>O<sub>2</sub>

In our current study, we examined the level of pERK to further assess whether fucoxanthin produced neuroprotective effects via the inhibition of the ERK pathway. Figure 10 displays that fucoxanthin pre-treatment significantly protected against the increase of pERK induced by H<sub>2</sub>O<sub>2</sub> at 0.5 h, suggesting that fucoxanthin also inhibited the ERK pathway activation.

### Discussion

In our study, we showed that fucoxanthin, a marine carotenoid, potentially protected against H<sub>2</sub>O<sub>2</sub>-induced neurotoxicity in SH-SY5Y cells and in primary CGNs. In addition, we found that the neuroprotective effects of fucoxanthin were concurrently mediated via the activation of the PI3-K/Akt cascade and inhibition of the ERK pathway.

Fucoxanthin has been shown to possess different health benefits, such as anti-obesity, anti-tumor, anti-inflammatory as well as hepatoprotective activities.[30] Therefore, fucoxanthin might be used as a drug or a



**Figure 10.** Fucoxanthin inhibits H<sub>2</sub>O<sub>2</sub>-induced increase of pERK level. SH-SY5Y cells were treated with fucoxanthin for 2 h, and then exposed to 150 μM H<sub>2</sub>O<sub>2</sub>. Western blot was used to detect pERK at 30 min after H<sub>2</sub>O<sub>2</sub> treatment. Data were presented as the mean ± SEM of three separate experiments; ##*p* < 0.01 vs. the control group, \*\**p* < 0.01 vs. H<sub>2</sub>O<sub>2</sub>-treated group (ANOVA and Tukey's test).

functional food to treat chronic diseases. We have recently reported that fucoxanthin can inhibit acetylcholinesterase and attenuate scopolamine-induced cognitive impairments in mice, indicating that this chemical can be used in the treatment of Alzheimer's disease.[31] However, it remains unclear whether fucoxanthin could produce neuroprotective effects. Recent studies have reported that fucoxanthin can prevent oxidative stress-induced cytotoxicity in microglia cells, hepatic cells and fibroblast cells.[13–16] Therefore, we first evaluated whether fucoxanthin protected against oxidative stress-induced neurotoxicity. Our data demonstrated that fucoxanthin protected against H<sub>2</sub>O<sub>2</sub>-induced neuronal death not only in SH-SY5Y cells, but also in primary CGNs, providing a strong support that fucoxanthin could produce neuroprotective effects, and it might be used in the treatment of neurodegenerative disorders.

How could fucoxanthin produce neuroprotective effects? Fucoxanthin belongs to the carotenoid group, which are potent antioxidants.[32] Fucoxanthin could quench singlet oxygen and scavenge free radicals, and therefore protect against cancer and inflammatory diseases.[33–35] In our study, we found that fucoxanthin could reduce H<sub>2</sub>O<sub>2</sub>-induced increase of intracellular ROS, suggesting that fucoxanthin, like other carotenoids, exerts its neuroprotective effects via the inhibition of oxidative stress. Previous studies have shown that fucoxanthin could act on many proteins, including the Bcl2 protein family, MAPK, NFκB and caspases to exert its functions.[36] Moreover, fucoxanthin could also regulate the mRNA expression of many proteins, such as TNF-α, MCP-1 and SCD1 in cells and animals.[37,38] We further anticipated that fucoxanthin acted on pro-survival and/or pro-apoptotic proteins which are involved in H<sub>2</sub>O<sub>2</sub>-induced oxidative stress. The PI3K/Akt pathway plays an important role in neuronal survival.[39] Phosphorylated Akt further induces the inhibition of GSK3β via phosphorylating its Ser-9 residue.[40] In our study, we found that fucoxanthin significantly protected against H<sub>2</sub>O<sub>2</sub>-induced reduction of pSer473-Akt and pSer9-GSK3β. We also demonstrated that a GSK3β specific inhibitor protected against H<sub>2</sub>O<sub>2</sub>-induced neuronal apoptosis, whereas PI3-K specific inhibitors abolished the neuroprotective effects of fucoxanthin, supporting the role of the PI3-K/Akt/GSK3β cascade in the neuroprotective effects of fucoxanthin. These data were in agreement with a previous study that fucoxanthin can activate the PI3-K/Akt cascade to reduce oxidative stress-induced cell injury in human keratinocytes.[41]

The ERK pathway is one of the key pathways mediating oxidative stress-induced neurotoxicity.[42] We found that fucoxanthin significantly protected against H<sub>2</sub>O<sub>2</sub>-induced enhancement of pERK. Furthermore, an MEK specific inhibitor protected against H<sub>2</sub>O<sub>2</sub>-induced neurotoxicity, suggesting that inhibition of the ERK pathway was also involved in the neuroprotective effects of fucoxanthin. These results were consistent with previous studies that fucoxanthin can inhibit the ERK pathway to ameliorate oxidative stress-induced cell injury in macrophages.[43] Taken together with our previous findings, we concluded that fucoxanthin could both activate the pro-survival PI3K/Akt cascade and inhibit the pro-apoptotic ERK pathway to produce its neuroprotective effects.

In the current study, we only performed cell culture experiments, which is a limitation. In a submitted study [44], we have found that fucoxanthin could prevent β-amyloid (Aβ) oligomer-induced abnormalities in learning and memory. Aβ oligomers are widely accepted as main neurotoxins to induce neuronal



impairments in Alzheimer's disease. A $\beta$  oligomers lead to neuronal death mainly via oxidative stress.[45] Therefore, these animal studies further confirmed our current findings that fucoxanthin might produce neuroprotective effects against oxidative stress-induced neurotoxicity.

In summary, we, for the first time, found that fucoxanthin protected against H<sub>2</sub>O<sub>2</sub>-induced apoptosis via concurrently activating the PI3K/Akt cascade and inhibiting the ERK pathway. Our results also provided support for the use of fucoxanthin in the treatment of neurodegenerative disorders caused or characterized by oxidative stress.

### Disclosure statement

No potential conflict of interest was reported by the authors.

### Funding

This work was financially supported by the Natural Science Foundation of Zhejiang Province (LY15H310007), the Ningbo International Science and Technology Cooperation Project (2014D10019), Ningbo Municipal Innovation Team of Life Science and Health (2015C110026), the Applied Research Project on Nonprofit Technology of Zhejiang Province (2016C37110), the National Natural Science Foundation of China (81673407, U1503223, 81202150, 81471398, 41406163, 41306134), Ningbo Natural Science Foundation (2015A610219), the Scientific Research Foundation for the Returned Overseas Chinese Scholars, the State Education Ministry, Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Development Fund, National 111 Project of China, and the K. C. Wong Magna Fund in Ningbo University.

### References

- [1] Kim GH, Kim JE, Rhie SJ, et al. The role of oxidative stress in neurodegenerative diseases. *Exp Neurobiol.* 2015;24:325–340.
- [2] Yoon SO, Yun CH, Chung AS. Dose effect of oxidative stress on signal transduction in aging. *Mech Ageing Dev.* 2002;123:1597–1604.
- [3] Lee KY, Koh SH, Noh MY, et al. Glycogen synthase kinase-3 $\beta$  activity plays very important roles in determining the fate of oxidative stress-inflicted neuronal cells. *Brain Res.* 2007;1129:89–99.
- [4] Gao Y, Dong C, Yin J, et al. Neuroprotective effect of fucoidan on H<sub>2</sub>O<sub>2</sub>-induced apoptosis in PC12 cells via activation of PI3K/Akt pathway. *Cell Mol Neurobiol.* 2012;32:523–529.
- [5] Lin X, Wu S, Wang Q, et al. Saikosaponin-D reduces HO-induced PC12 cell apoptosis by removing ROS and blocking MAPK-dependent oxidative damage. *Cell Mol Neurobiol.* 2016;36(8):1365–1375.
- [6] Yang LY, Ko WC, Lin CM, et al. Antioxidant N-acetylcysteine blocks nerve growth factor-induced H<sub>2</sub>O<sub>2</sub>/ERK signaling in PC12 cells. *Ann N Y Acad Sci.* 2005;1042:325–337.
- [7] D'Orazio N, Gammone MA, Gemello E, et al. Marine bioactives: pharmacological properties and potential applications against inflammatory diseases. *Mar Drugs.* 2012;10:812–833.
- [8] Das SK, Hashimoto T, Kanazawa K. Growth inhibition of human hepatic carcinoma HepG2 cells by fucoxanthin is associated with down-regulation of cyclin D. *Biochim Biophys Acta.* 2008;1780:743–749.
- [9] Woo MN, Jeon SM, Shin YC, et al. Anti-obese property of fucoxanthin is partly mediated by altering lipid-regulating enzymes and uncoupling proteins of visceral adipose tissue in mice. *Mol Nutr Food Res.* 2009;53:1603–1611.
- [10] Maeda H, Hosokawa M, Sashima T, et al. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. *J Agric Food Chem.* 2007;55:7701–7706.
- [11] Gammone MA, D'Orazio N. Anti-obesity activity of the marine carotenoid fucoxanthin. *Mar Drugs.* 2015;13:2196–2214.
- [12] Ha AW, Na SJ, Kim WK. Antioxidant effects of fucoxanthin rich powder in rats fed with high fat diet. *Nutr Res Pract.* 2013;7:475–480.
- [13] Pangestuti R, Vo TS, Ngo DH, et al. Fucoxanthin ameliorates inflammation and oxidative responses in microglia. *J Agric Food Chem.* 2013;61:3876–3883.
- [14] Liu CL, Liang AL, Hu ML. Protective effects of fucoxanthin against ferric nitrilotriacetate-induced oxidative stress in murine hepatic BNL CL2 cells. *Toxicol In Vitro.* 2011;25:1314–1319.
- [15] Zheng J, Piao MJ, Keum YS, et al. Fucoxanthin protects cultured human keratinocytes against oxidative stress by blocking free radicals and inhibiting apoptosis. *Biomol Ther (Seoul).* 2013;21:270–276.
- [16] Heo SJ, Jeon YJ. Protective effect of fucoxanthin isolated from *Sargassum siliquastrum* on UV-B induced cell damage. *J Photochem Photobiol B.* 2009;95:101–107.
- [17] Li X, Song L, Jope RS. Cholinergic stimulation of AP-1 and NF kappa B transcription factors is differentially sensitive to oxidative stress in SH-SY5Y neuroblastoma: relationship to phosphoinositide hydrolysis. *J Neurosci.* 1996;16:5914–5922.
- [18] Nirmaladevi D, Venkataramana M, Chandranayaka S, et al. Neuroprotective effects of bikaverin on H<sub>2</sub>O<sub>2</sub>-induced oxidative stress mediated neuronal damage in SH-SY5Y cell line. *Cell Mol Neurobiol.* 2014;34:973–985.
- [19] Tian X, Guo LP, Hu XL, et al. Protective effects of *Arctium lappa* L. roots against hydrogen peroxide-induced cell injury and potential mechanisms in SH-SY5Y cells. *Cell Mol Neurobiol.* 2015;35:335–344.
- [20] González-Polo RA, Soler G, Fuentes JM. MPP<sup>+</sup> mechanism for its toxicity in cerebellar granule cells. *Mol Neurobiol.* 2004;30:253–264.
- [21] Luo J, Li W, Zhao Y, et al. Pathologically activated neuroprotection via uncompetitive blockade of N-methyl-D-aspartate receptors with fast off-rate by

- novel multifunctional dimer bis(propyl)-cognitin. *J Biol Chem.* **2010**;285:19947–19958.
- [22] Cui W, Zhang Z, Li W, et al. The anti-cancer agent SU4312 unexpectedly protects against MPP(+)-induced neurotoxicity via selective and direct inhibition of neuronal NOS. *Br J Pharmacol.* **2013**;168:1201–1214.
- [23] Cui W, Zhang ZJ, Hu SQ, et al. Sunitinib produces neuroprotective effect via inhibiting nitric oxide overproduction. *CNS Neurosci Ther.* **2014**;20:244–252.
- [24] Jones KH, Senft JA. An improved method to determine cell viability by simultaneous staining with fluorescein diacetate-propidium iodide. *J Histochem Cytochem.* **1985**;33:77–79.
- [25] Cui W, Zhang Z, Li W, et al. Unexpected neuronal protection of SU5416 against 1-Methyl-4-phenylpyridinium ion-induced toxicity via inhibiting neuronal nitric oxide synthase. *Plos One.* **2012**;7:e46253.
- [26] Hu S, Wang R, Cui W, et al. Inhibiting beta-amyloid-associated Alzheimer's pathogenesis in vitro and in vivo by a multifunctional dimeric Bis(12)-huprydone derived from its natural analogue. *J Mol Neurosci.* **2014**;55(4):1014–1021.
- [27] Hu SQ, Cui W, Zhang ZJ, et al. Indirubin-3-oxime effectively prevents 6OHDA-induced neurotoxicity in PC12 cells via activating MEF2D through the inhibition of GSK3 beta. *J Mol Neurosci.* **2015**;57:561–570.
- [28] Hu SQ, Cui W, Xu DP, et al. Substantial neuroprotection against K<sup>+</sup> deprivation-induced apoptosis in primary cerebellar granule neurons by novel dimer bis(propyl)-cognitin via the activation of VEGFR-2 signaling pathway. *CNS Neurosci Ther.* **2013**;19:764–772.
- [29] Cui W, Li W, Zhao Y, et al. Preventing H(2)O(2)-induced apoptosis in cerebellar granule neurons by regulating the VEGFR-2/Akt signaling pathway using a novel dimeric antiacetylcholinesterase bis(12)-huprydone. *Brain Res.* **2011**;1394:14–23.
- [30] Zhang H, Tang Y, Zhang Y, et al. Fucoxanthin: a promising medicinal and nutritional ingredient. *Evid Based Complement Alternat Med.* **2015**;2015:723515.
- [31] Lin J, Huang L, Yu J, et al. Fucoxanthin, a marine carotenoid, reverses scopolamine-induced cognitive impairments in mice and inhibits acetylcholinesterase in vitro. *Mar Drugs.* **2016**;14:67.
- [32] Gammone MA, Riccioni G, D'Orazio N. Marine carotenoids against oxidative stress: effects on human health. *Marine Drugs.* **2015**;13:6226–6246.
- [33] Hu TT, Liu D, Chen Y, et al. Antioxidant activity of sulfated polysaccharide fractions extracted from *Undaria pinnatifida* in vitro. *Int J Biol Macromol.* **2010**;46:193–198.
- [34] D'Orazio N, Gemello E, Gammone MA, et al. Fucoxanthin: a treasure from the sea. *Marine Drugs.* **2012**;10:604–616.
- [35] Park HJ, Lee MK, Park YB, et al. Beneficial effects of *Undaria pinnatifida* ethanol extract on diet-induced-insulin resistance in C57BL/6J mice. *Food Chem Toxicol.* **2011**;49:727–733.
- [36] Kumar SR, Hosokawa M, Miyashita K. Fucoxanthin: a marine carotenoid exerting anti-cancer effects by affecting multiple mechanisms. *Marine Drugs.* **2013**;11:5130–5147.
- [37] Beppu F, Hosokawa M, Yim MJ, et al. Down-regulation of hepatic stearoyl-CoA desaturase-1 expression by fucoxanthin via leptin signaling in diabetic/obese KK-A (y) mice. *Lipids.* **2013**;48:449–455.
- [38] Maeda H, Kanno S, Kodate M, et al. Fucoxanthinol, metabolite of fucoxanthin, improves obesity-induced inflammation in adipocyte cells. *Marine Drugs.* **2015**;13:4799–4813.
- [39] Heras-Sandoval D, Pérez-Rojas JM, Hernández-Damián J, et al. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. *Cell Signal.* **2014**;26:2694–2701.
- [40] Frebel K, Wiese S. Signalling molecules essential for neuronal survival and differentiation. *Biochem Soc Trans.* **2006**;34:1287–1290.
- [41] Zheng J, Piao MJ, Kim KC, et al. Fucoxanthin enhances the level of reduced glutathione via the Nrf2-mediated pathway in human keratinocytes. *Mar Drugs.* **2014**;12:4214–4230.
- [42] Jiang H, Zhang L, Koubi D, et al. Roles of Ras-Erk in apoptosis of PC12 cells induced by trophic factor withdrawal or oxidative stress. *J Mol Neurosci.* **2005**;25:133–140.
- [43] Kim KN, Heo SJ, Yoon WJ, et al. Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-kappaB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. *Eur J Pharmacol.* **2010**;649:369–375.
- [44] Xiang S, Liu FLin J, et al. (submitted). Fucoxanthin inhibits  $\beta$ -amyloid assembly and attenuates  $\beta$ -amyloid oligomer-induced cognitive impairments. *J. Agric. Food. Chem.*
- [45] Luque-Contreras D, Carvajal K, Toral-Rios D, et al. Oxidative stress and metabolic syndrome: cause or consequence of Alzheimer's disease? *Oxid Med Cell Longev.* **2014**;5:497802.